GLP-1 medications have been life changing for so many people with obesity, says Jody Dushay, MD, an assistant professor of medicine at Harvard Medical School and an endocrinologist at the Beth Israel Deaconess Medical Center in Boston
This piece covers exactly how alcohol interferes with CJC-1295 and Ipamorelin at the receptor level, what the research shows about timing windows, and what dosing strategies can minimize the interaction if alcohol consumption is unavoidable
The loss of patent protections, the development of cheaper pill formats, and a focus on the previously discovered health benefits of semaglutide, like prevention of kidney and heart disease which will encourage more coverage from governments and insurers all point to the cost barrier weakening significantly in the near future
Understanding how it compares to semaglutide and other GLP-1 receptor agonists provides useful context, especially if you are switching between medications or using multiple compounds